Gelonghui, May 9丨Xinhua Pharmaceutical (000756.SZ) said on the investor interactive platform that the company has continued to increase R&D investment in recent years, reaching 406 million yuan in R&D in 2023. The company carries out research and development work on cardiovascular, antipyretic and analgesic, digestive, anti-metabolic, neurological, narcotic drugs, etc., including innovative drugs and generic drugs. There are more than 100 drugs entering the R&D pipeline. R&D strategies include: first, combining the characteristics and advantages of the enterprise's entire industry chain, starting from technical quality advantages, cost advantages, supporting advantages, etc.; second, combining development ideas to strengthen the domestic market and expand the international market, selecting competitive products to double report between China and the US; third, highlighting high value-added products such as high imitation and first imitation; and fourth, multiple types of innovative drugs are in the R&D pipeline. In 2023, the “Green Channel Management Measures for R&D and Transformation (Trial)”, “Management Measures for the Assessment of Innovative Breakthrough Development Projects (Trial)”, and “Management Measures for Incentives for the Whole Life Cycle of Science and Technology Innovation (Trial)” were formulated and implemented. In 2023, 26 drug approvals and 15 veterinary drug approvals were obtained, a record high. Three new class I drugs are in phase 1 or phase 2 clinical phase.